Maze Therapeutics (NASDAQ:MAZE) Raised to Strong-Buy at Leerink Partnrs

Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Other equities research analysts have also issued research reports about the stock. JPMorgan Chase & Co. began coverage on shares of Maze Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $30.00 target price on the stock. Leerink Partners began coverage on shares of Maze Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $28.00 price objective on the stock. Finally, Guggenheim began coverage on shares of Maze Therapeutics in a research note on Tuesday. They set a “buy” rating and a $19.00 price objective on the stock.

Maze Therapeutics Price Performance

NASDAQ:MAZE opened at $10.57 on Tuesday. Maze Therapeutics has a 1-year low of $10.08 and a 1-year high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.